Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the U.S.for novel treatments such as Gilead Sciences' Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday.
Drug spending tops $1 trillion on hepatitis C, cancer therapies
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.